DK1482919T3 - Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes - Google Patents
Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetesInfo
- Publication number
- DK1482919T3 DK1482919T3 DK02710518T DK02710518T DK1482919T3 DK 1482919 T3 DK1482919 T3 DK 1482919T3 DK 02710518 T DK02710518 T DK 02710518T DK 02710518 T DK02710518 T DK 02710518T DK 1482919 T3 DK1482919 T3 DK 1482919T3
- Authority
- DK
- Denmark
- Prior art keywords
- patients
- diabetes
- type
- combination
- pharmaceutical composition
- Prior art date
Links
- 239000008280 blood Substances 0.000 title abstract 3
- 210000004369 blood Anatomy 0.000 title abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 2
- 239000013543 active substance Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 239000008103 glucose Substances 0.000 abstract 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
- WIGIZIANZCJQQY-RUCARUNLSA-N glimepiride Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)N[C@@H]2CC[C@@H](C)CC2)C=C1 WIGIZIANZCJQQY-RUCARUNLSA-N 0.000 abstract 1
- 229960004346 glimepiride Drugs 0.000 abstract 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 abstract 1
- 229960003105 metformin Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000009097 single-agent therapy Methods 0.000 abstract 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/MX2002/000003 WO2003061643A1 (es) | 2002-01-25 | 2002-01-25 | Composicion farmaceutica para el control de la glucosa en sangre de pacientes con diabetes tipo 2 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1482919T3 true DK1482919T3 (da) | 2007-07-30 |
Family
ID=27607097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02710518T DK1482919T3 (da) | 2002-01-25 | 2002-01-25 | Farmaceutisk sammensætning til blodsukkerkontrol hos patienter med type 2 diabetes |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9045438B2 (da) |
| EP (1) | EP1482919B1 (da) |
| AT (1) | ATE361065T1 (da) |
| BR (1) | BRPI0502691A (da) |
| CY (1) | CY1106771T1 (da) |
| DE (1) | DE60219963T2 (da) |
| DK (1) | DK1482919T3 (da) |
| ES (1) | ES2284829T3 (da) |
| MX (1) | MXPA04007183A (da) |
| PT (1) | PT1482919E (da) |
| WO (1) | WO2003061643A1 (da) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE361065T1 (de) | 2002-01-25 | 2007-05-15 | Silanes Sa De Cv Lab | Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes |
| WO2003105809A1 (en) | 2002-06-17 | 2003-12-24 | Themis Laboratories Private Limited | Multilayer tablets containing thiazolidinedione and biguanides and methods for producing them |
| MXPA05009633A (es) * | 2005-09-08 | 2007-03-07 | Silanes Sa De Cv Lab | Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada. |
| FR2896157B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents de stimulation de secretion d'insuline. |
| BR112012026005A2 (pt) * | 2010-04-13 | 2015-09-08 | Nucitec Sa De Cv | composições e métodos para tratar diabetes do tipo ii e distúrbios relacionados |
| MX339374B (es) * | 2011-04-29 | 2016-05-13 | Inst De Investigación En Química Aplic S A De C V | Cocristales ionicos con base en metformina. |
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| EP2712628B1 (en) * | 2012-09-28 | 2016-08-10 | Shanta Banerjee | Composition for use as a medicine or dietetic food, in particular in the prevention and/or treatment of Diabetes and diabetes associated diseases |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| US9898585B2 (en) | 2014-01-31 | 2018-02-20 | Aseko, Inc. | Method and system for insulin management |
| EP3933845A3 (en) | 2014-10-27 | 2022-06-22 | Aseko, Inc. | Subcutaneous outpatient management |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| WO2016168388A2 (en) | 2015-04-14 | 2016-10-20 | Palatin Technologies, Inc. | Therapies for obesity, diabetes and related indications |
| EP3337402B1 (en) | 2015-08-20 | 2026-01-07 | Glytec, LLC | Diabetes management therapy advisor |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3072527A (en) * | 1959-07-01 | 1963-01-08 | Horner Frank W Ltd | Use of tolbutamide in the treatment of acne |
| JP3465247B2 (ja) * | 1992-12-28 | 2003-11-10 | アベンティス ファーマ株式会社 | 動脈硬化症の予防および治療剤 |
| DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
| US6348469B1 (en) * | 1995-04-14 | 2002-02-19 | Pharma Pass Llc | Solid compositions containing glipizide and polyethylene oxide |
| IT1276130B1 (it) | 1995-11-14 | 1997-10-27 | Gentili Ist Spa | Associazione glibenclamide-metformina, composizioni farmaceutiche che la contengono e loro uso nel trattamento del diabete mellito di tipo |
| US6011049A (en) * | 1997-02-19 | 2000-01-04 | Warner-Lambert Company | Combinations for diabetes |
| ATE261935T1 (de) * | 1997-12-08 | 2004-04-15 | Bristol Myers Squibb Co | Neue metformin salze und verfahren |
| ATE250418T1 (de) * | 1998-07-15 | 2003-10-15 | Merck Sante Sas | Tabletten enthaltend eine kombination von glibenclamid und metformin |
| DE19860698A1 (de) | 1998-12-30 | 2000-07-06 | Hexal Ag | Neue pharmazeutische Zusammensetzung |
| US6559188B1 (en) * | 1999-09-17 | 2003-05-06 | Novartis Ag | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| US6586438B2 (en) | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
| US6499984B1 (en) * | 2000-05-22 | 2002-12-31 | Warner-Lambert Company | Continuous production of pharmaceutical granulation |
| YU8803A (sh) * | 2000-08-07 | 2006-01-16 | Ranbaxy Signature L.L.C. | Tečni oblik metformina |
| FR2825023B1 (fr) * | 2001-05-23 | 2005-04-15 | Flamel Tech Sa | Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif |
| ATE361065T1 (de) | 2002-01-25 | 2007-05-15 | Silanes Sa De Cv Lab | Pharmazeutische zusammensetzung zur kontrolle des blutzuckers bei patienten mit typ 2 diabetes |
| US6682759B2 (en) * | 2002-02-01 | 2004-01-27 | Depomed, Inc. | Manufacture of oral dosage forms delivering both immediate-release and sustained-release drugs |
| US20030187074A1 (en) * | 2002-03-04 | 2003-10-02 | Javed Hussain | Oral compositions for treatment of diabetes |
| WO2004045622A1 (en) | 2002-11-15 | 2004-06-03 | Ranbaxy Laboratories Limited | Pharmaceutical dosage forms of biguanide-sulfonylurea combinations |
| MXPA05009633A (es) * | 2005-09-08 | 2007-03-07 | Silanes Sa De Cv Lab | Composicion farmaceutica estable de glimepirida de liberacion inmediata y metformina de liberacion prolongada. |
-
2002
- 2002-01-25 AT AT02710518T patent/ATE361065T1/de active
- 2002-01-25 WO PCT/MX2002/000003 patent/WO2003061643A1/es not_active Ceased
- 2002-01-25 ES ES02710518T patent/ES2284829T3/es not_active Expired - Lifetime
- 2002-01-25 MX MXPA04007183A patent/MXPA04007183A/es active IP Right Grant
- 2002-01-25 US US10/502,403 patent/US9045438B2/en not_active Expired - Fee Related
- 2002-01-25 DE DE60219963T patent/DE60219963T2/de not_active Expired - Lifetime
- 2002-01-25 PT PT02710518T patent/PT1482919E/pt unknown
- 2002-01-25 DK DK02710518T patent/DK1482919T3/da active
- 2002-01-25 EP EP02710518A patent/EP1482919B1/en not_active Expired - Lifetime
-
2005
- 2005-07-08 BR BRPI0502691-1A patent/BRPI0502691A/pt not_active Application Discontinuation
-
2007
- 2007-07-30 CY CY20071101008T patent/CY1106771T1/el unknown
-
2015
- 2015-06-01 US US14/727,396 patent/US20160051511A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| MXPA04007183A (es) | 2006-03-06 |
| US9045438B2 (en) | 2015-06-02 |
| US20050239887A1 (en) | 2005-10-27 |
| US20160051511A1 (en) | 2016-02-25 |
| DE60219963D1 (de) | 2007-06-14 |
| ATE361065T1 (de) | 2007-05-15 |
| PT1482919E (pt) | 2007-07-25 |
| BRPI0502691A (pt) | 2006-03-07 |
| ES2284829T3 (es) | 2007-11-16 |
| EP1482919B1 (en) | 2007-05-02 |
| WO2003061643A1 (es) | 2003-07-31 |
| CY1106771T1 (el) | 2012-05-23 |
| DE60219963T2 (de) | 2008-02-07 |
| EP1482919A1 (en) | 2004-12-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1106771T1 (el) | Φαρμακευτικη συνθεση η οποια χρησιμοποιειται για τον ελεγχο της γλυκοζης του αιματος σε ασθενεις με διαβητη τυπου 2 | |
| BR9907866A (pt) | Composição farmacêutica compreendendo uma combinação de metformina e fibrato, e seu uso para a preparação de medicinas destinadas a reduzir a hiperglicemia | |
| BR112023000229A2 (pt) | Composto, composição farmacêutica, e, peptídeo | |
| DE60236541D1 (de) | Inhibitoren von 11-beta-hydroxysteroiddehydrogenase typ 1 | |
| UY26425A1 (es) | Formulación y método antidiabético | |
| BR0109336A (pt) | Medicamento para a prevenção, melhora e/ou tratamento de uma complicação diabética, droga medicinal adequada ou utilizável como o mesmo, método para prevenir, melhorar e/ou tratar a complicação diabética, e a neuropatia, e, usos de um agente redutor do açúcar no sangue pós-prandial e pelo menos um agente selecionado de um agente anti-hipertensivo, um agente vasodilatador e um agente anti-hiperlipidêmico | |
| BRPI0508540A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| EA200900626A1 (ru) | Комбинированное лечение ингибиторами sglt-2 (натрийзависимый сопереносчик глюкозы 2) и содержащими их фармацевтическими композициями | |
| NO20073059L (no) | 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists | |
| WO2005039485A3 (en) | Gsk-3 inhibitors and uses thereof | |
| BR112023000270A2 (pt) | Composto, composição farmacêutica, e, peptídeo | |
| DE602005021770D1 (de) | Indol-1-yl-essigsäurederivate | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| ATE494889T1 (de) | Pharmazeutische kombination mit 3- (3- dimethylamino-1-ethyl-2-methyl-propyl)-phenol und paracetamol | |
| NZ591408A (en) | Paracetamol and Calcium carbonate composition | |
| BRPI0418742A (pt) | métodos de tratamento, prevenção ou controle de uma sìndrome mielodisplásica, de redução ou evitação de um efeito adverso associado com a administração de um segundo ingrediente ativo em um paciente sofrendo de um sìndrome mielodisplásica, composição farmacêutica, forma de dosagem unitária única, e, kit | |
| BRPI0409878A (pt) | compostos, composições farmacêuticas, método para o tratamento ou profilaxia de doenças, e, usos de compostos e de um ou mais compostos em combinação com outros compostos farmacologicamente ativos | |
| TR200200913T2 (tr) | Bir NK1 reseptörü antagonistini ve bir gaba yapısal analoğunun sinerjik kombinasyonları. | |
| BRPI0410761A (pt) | uso de leucina, e, composição para administração entérica a pacientes | |
| WO2007064448A3 (en) | Cancer treatment using fts and 2-deoxyglucose | |
| PE20030277A1 (es) | Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa | |
| DE60321175D1 (de) | Dichloracetat in kombination mit kardioprotektiven oder hämodynamischen medikamenten | |
| SE0203817D0 (sv) | New composition | |
| BRPI0414112A (pt) | uso de oxcarbazepina para o tratamento de dor neuropática diabética e a melhora do sono | |
| WO2003082283A3 (en) | Pharmaceutical composition with combined active agents and methods for using the same |